Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
Agalsidase beta, a form of recombinant human α-galactosidase A (αGAL), is approved for use as enzyme replacement therapy (ERT) for Fabry disease. An immunogenic response against a therapeutic protein could potentially impact its efficacy or safety. The development of anti-αGAL IgG antibodies was evaluated in 571 men and 251 women from the Fabry Registry who were treated with agalsidase beta. Most men developed antibodies (416 of 571, 73%), whereas most women did not (31 of 251, 12%). Women were also significantly more likely to tolerize than men; whereas 18 of 31 women tolerized (58%, 95%CI: 52%-64%), only 47 of 416 men tolerized during the observation period (11%, 95% CI: 8%-15%). Patients who eventually tolerized had lower median peak anti-αGAL IgG antibody titers than patients who remained seropositive at their most recent assessment (400 versus 3200 in men, 200 versus 400 in women, respectively). Patients with nonsense mutations in the GLA gene were more likely to develop anti-αGAL IgG antibodies than patients with missense mutations. Approximately 26% of men (151 of 571) reported infusion-associated reactions (IARs), compared to 11% of women (27 of 251). Men who developed anti-αGAL IgG antibodies were more likely to experience IARs compared to those who remained seronegative. Nine percent of seronegative men and women (34 of 375) reported IARs. The majority of IARs occurred during the first 6 to 12 months of agalsidase beta treatment and decreased over time, in both seroconverted and seronegative patients.
Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. bill.wilcox@cshs.org
William R
WR
Wilcox
Gabor E
GE
Linthorst
Dominique P
DP
Germain
Ulla
U
Feldt-Rasmussen
Stephen
S
Waldek
Susan M
SM
Richards
Dana
D
Beitner-Johnson
Marta
M
Cizmarik
J Alexander
JA
Cole
Wytske
W
Kingma
David G
DG
Warnock
D000917:Antibody Formation; D018389:Codon, Nonsense; D056947:Enzyme Replacement Therapy / Q000379:methods; D000795:Fabry Disease / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis* / Q000276:immunology; D007527:Isoenzymes / Q000276:immunology* / Q000627:therapeutic use*; D008297:Male; D020125:Mutation, Missense; D016896:Treatment Outcome; D000519:alpha-Galactosidase / Q000276:immunology* / Q000627:therapeutic use
D018389:Codon, Nonsense; D007074:Immunoglobulin G; D007527:Isoenzymes; D000519:alpha-Galactosidase; C459420:agalsidase beta